Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

276 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial.
Martin RM, Turner EL, Young GJ, Metcalfe C, Walsh EI, Lane JA, Sterne JAC, Noble S, Holding P, Ben-Shlomo Y, Williams NJ, Pashayan N, Bui MN, Albertsen PC, Seibert TM, Zietman AL, Oxley J, Adolfsson J, Mason MD, Davey Smith G, Neal DE, Hamdy FC, Donovan JL; CAP Trial Group. Martin RM, et al. Among authors: zietman al. JAMA. 2024 May 7;331(17):1460-1470. doi: 10.1001/jama.2024.4011. JAMA. 2024. PMID: 38581198 Clinical Trial.
Long-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524-A Phase 1/2 Trial of Paclitaxel + Trastuzumab with Daily Radiation or Paclitaxel Alone with Daily Irradiation.
Dahl DM, Karrison TG, Michaelson MD, Pham HT, Wu CL, Swanson GP, Shipley WU, Vuky J, Lee RJ, Zietman AL, Souhami L, Chang BK, Deming RL, Ellerton JA, Sandler HM, Rodgers JP, Feng FY, Efstathiou JA. Dahl DM, et al. Among authors: zietman al. Eur Urol Oncol. 2024 Feb;7(1):83-90. doi: 10.1016/j.euo.2023.05.013. Epub 2023 Jul 11. Eur Urol Oncol. 2024. PMID: 37442672 Clinical Trial.
Gender-Affirming Surgery and Cancer: Considerations for Radiation Oncologists for Pelvic Radiation in Transfeminine Patients.
Smart AC, Liu KX, Domogauer JD, Rodriguez-Russo C, Jones B, Dickstein DR, Mancias JD, Shiloh RY, Wintner A, Zietman AL, Marshall DC, Dyer MA, Russo AL. Smart AC, et al. Among authors: zietman al. Int J Radiat Oncol Biol Phys. 2023 Oct 1;117(2):301-311. doi: 10.1016/j.ijrobp.2023.05.028. Epub 2023 May 24. Int J Radiat Oncol Biol Phys. 2023. PMID: 37230432 Review.
Impact of a negative confirmatory biopsy on risk of disease progression among men on active surveillance for prostate cancer.
Salari K, Kowitz J, Twum-Ampofo J, Gusev A, O'Shea A, Anderson MA, Harisinghani M, Kuppermann D, Dahl DM, Efstathiou JA, Lee RJ, Blute ML, Zietman AL, Feldman AS. Salari K, et al. Among authors: zietman al. Urol Oncol. 2023 Sep;41(9):387.e9-387.e16. doi: 10.1016/j.urolonc.2023.04.018. Epub 2023 May 17. Urol Oncol. 2023. PMID: 37208229
Impact of an Expanded Definition of Family History on Outcomes of Active Surveillance for Prostate Cancer.
Schneider AC, Chandrasekar T, Bowler N, Fogg R, Leong JY, Gusev A, Rodgers LH, McCormick SR, Dahl DM, Efstathiou JA, Blute ML, Zietman AL, Wu CL, Smith MR, Van Allen EM, Feldman AS, Salari K. Schneider AC, et al. Among authors: zietman al. J Urol. 2023 Jun;209(6):1112-1119. doi: 10.1097/JU.0000000000003396. Epub 2023 Mar 9. J Urol. 2023. PMID: 36951811
Analysis of MRE11 and Mortality Among Adults With Muscle-Invasive Bladder Cancer Managed With Trimodality Therapy.
Magliocco AM, Moughan J, Miyamoto DT, Simko J, Shipley WU, Gray PJ, Hagan MP, Parliament M, Tester WJ, Zietman AL, McCarthy S, Saeed-Vafa D, Xiong Y, Ayral T, Hartford AC, Patel A, Rosenthal SA, Chafe S, Greenberg R, Schwartz MA, Augspurger ME, Keech JA Jr, Winter KA, Feng FY, Efstathiou JA. Magliocco AM, et al. Among authors: zietman al. JAMA Netw Open. 2022 Nov 1;5(11):e2242378. doi: 10.1001/jamanetworkopen.2022.42378. JAMA Netw Open. 2022. PMID: 36383379 Free PMC article.
276 results